The Latest Cardiac and Vascular News
HUNTINGTON BEACH, Calif. & HOUSTON & GOLD COAST, Australia–(BUSINESS WIRE)–BiVACOR, Inc., a clinical-stage medical technology company developing a total artificial heart (TAH), today announced that Jim Dillon has been named chief executive officer and a member of its board of directors. “We are thrilled to have him join as CEO.” […]
NEW YORK–(BUSINESS WIRE)–Artificial Intelligence (AI)-driven Primary Care company K Health announces today the next phase of its quest to tackle the prevention and care of heart-related conditions. It has entered into a know-how agreement with Mayo Clinic to collaborate with Mayo Clinic cardiologists Francisco Lopez-Jimenez, M.D., M.S., MBA, Chair of the Division […]
MOUNTAIN VIEW, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) — HeartFlow, Inc., a leader in non-invasive artificial intelligence (AI) precision coronary care solutions, today announced that it has surpassed 250,000 patients receiving a HeartFlow FFRCT Analysis. This accomplishment is a testament to HeartFlow’s dedication to driving a new standard of care […]
MINNEAPOLIS, Jan. 3, 2024 /PRNewswire/ — Cardionomic, Inc., a Minneapolis medical device company, is pleased to announce the completion of enrollment in both their STIM-ADHF and STOP-ADHF pilot studies. Both studies were designed to evaluate the safety and performance of the Cardiac…
$6M early-stage biotech investment supplemented by $2.3M non-dilutive grant funding ENCINITAS, Calif., Jan. 3, 2024 /PRNewswire/ — Vasa Therapeutics, Inc. (“Vasa”), a preclinical stage biopharmaceutical company developing novel therapies for cardiovascular aging, announced today the…
MINNEAPOLIS, Jan. 2, 2024 /PRNewswire/ — Norway-based CardioMech AS, a medical device company developing a transfemoral, transseptally delivered mitral valve chordal repair technology in Fridley, MN, today announced it has closed on $13M in fresh capital ($42M to-date). CardioMech received strong financial support from existing and new investors, including a non-disclosed strategic investor. The heavily oversubscribed round […]
The new preclinical data further supports istaroxime clinical data from three Phase 2 studies Arrythmias can be a serious complication of current rescue therapies for treatment of patients with acute heart failure WARRINGTON, Pa., Jan. 02, 2024 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology […]
BRAINTREE, Mass., Jan. 2, 2024 /PRNewswire/ — In a significant move to enhance their impact on global cardiac care, PrepMD and its subsidiaries, including PrepMD RMS, have unified under a single brand name and logo: ‘PrepMD’. This strategic decision marks a key milestone in their ongoing…
CHICAGO–(BUSINESS WIRE)–Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), an AI-driven precision cardiovascular medicine company, today announced that the American Medical Association (AMA) has assigned a dedicated Current Procedural Terminology (CPT®) Proprietary Laboratory Analysis (PLA), 0440U, for the company’s AI-driven coronary heart disease (CHD) detection test, PrecisionCHD. Receipt of this new CPT […]
HAYWARD, Calif.–(BUSINESS WIRE)–Pulse Biosciences, Inc. (Nasdaq: PLSE), a company primarily focused on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced the filing of a premarket notification 510(k) to the U.S. Food and Drug Administration (FDA) for its novel […]
